Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. - Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; et al. (Critical care medicine, 2001)